Annovis Bio Files 8-K on Financials
Ticker: ANVS · Form: 8-K · Filed: Apr 3, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Apr 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Annovis Bio dropped an 8-K on April 3rd detailing their financial condition as of April 2nd.
AI Summary
Annovis Bio, Inc. filed an 8-K on April 3, 2024, reporting on its results of operations and financial condition as of April 2, 2024. The filing details financial statements and exhibits related to the company's performance.
Why It Matters
This filing provides investors with an update on Annovis Bio's financial health and operational results, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not contain new material events or significant risk factors.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- April 2, 2024 (date) — Earliest event reported
- April 3, 2024 (date) — Filing date
- 101 Lindenwood Drive, Suite 225 Malvern, PA 19355 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Annovis Bio, Inc.'s results of operations and financial condition.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on April 2, 2024.
What is the filing date of this 8-K?
This 8-K was filed on April 3, 2024.
What is the principal executive office address for Annovis Bio, Inc.?
The principal executive office address for Annovis Bio, Inc. is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What is the SIC code for Annovis Bio, Inc.?
The Standard Industrial Classification (SIC) code for Annovis Bio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-04-02 18:22:14
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2410669d1_8k.htm (8-K) — 26KB
- tm2410669d1_ex99-1.htm (EX-99.1) — 25KB
- tm2410669d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-042695.txt ( ) — 233KB
- anvs-20240402.xsd (EX-101.SCH) — 3KB
- anvs-20240402_lab.xml (EX-101.LAB) — 33KB
- anvs-20240402_pre.xml (EX-101.PRE) — 22KB
- tm2410669d1_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On April 2, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the fourth quarter and the fiscal year ended December 31, 2023 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
01 Financial
Item 9.01 Financial (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated April 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: April 2, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer